COLL Collegium Pharmaceutical Inc.

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

Media Contact:

Cheryl Wheeler

Head of Corporate Communications





EN
24/04/2025

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report First Quarter 2025 Financial Results on May 8, 202...

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2025 Earnings Call.” An audio webcast will...

10h / 24m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in 24th Annual Needham Virtual Healthcare Con...

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website ...

April 1, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present Real-World Data at PainConnect 2025, the American...

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. Among these, the poster titled “Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids” h...

March 27, 2025 1 EN
Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 2 directors

Two Directors at Collegium Pharmaceutical Inc sold 28,410 shares at between 30.025USD and 30.027USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

COLL COLLEGIUM PHARMACEUTICAL INC.
03/24/25 March 24, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces Updates to its Board of Directors and Executive Le...

Collegium Announces Updates to its Board of Directors and Executive Leadership Team        – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People Officer – STOUGHTON, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COLL)...

March 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch